CD26/Dipeptidyl Peptidase IV and Its Multiple Biological Functions

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2021 Mar 29

PMID 33777580

Citations 14

Authors

Kelsey Pan

Kei Ohnuma

Chikao Morimoto

Nam H Dang

Affiliations

Soon will be listed here.

Abstract

CD26/Dipeptidyl peptidase IV (DPPIV) is a cell surface glycoprotein with numerous roles including glucose metabolism, immunomodulation, and tumorigenesis. CD26/DPPIV is well recognized in diabetes, with DPPIV inhibitors being a class of oral hypoglycemic drugs called gliptins that are commonly used to treat type two diabetes mellitus. Recent work also indicated a potential role for CD26 in infectious diseases, including COVID-19, and immune-mediated disorders such as rheumatoid arthritis, inflammatory bowel disease, and graft-versus-host disease. In cancer, CD26/DPPIV expression has been characterized in numerous tumors such as hematologic malignancies, malignant pleural mesothelioma (MPM), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), gastrointestinal stromal tumor (GIST), and prostate, lung, colorectal, and ovarian (PLCO) cancer. Hence, CD26 has been frequently studied as a tumor biomarker and therapeutic target. CD26/DPPIV-targeted therapies have been evaluated in various cancers, including the use of anti-CD26 monoclonal antibodies as anticancer treatment in selected neoplasms. This review highlights our current understanding of the role of CD26 in cancer, diabetes, immune-mediated diseases, and infectious diseases. Enhanced understanding of CD26 biology and function may lead to novel therapeutic approaches in multiple human diseases.

Citing Articles

The Role of Fibroblasts in Skin Homeostasis and Repair.

Boraldi F, Lofaro F, Bonacorsi S, Mazzilli A, Garcia-Fernandez M, Quaglino D Biomedicines. 2024; 12(7).

PMID: 39062158 PMC: 11274439. DOI: 10.3390/biomedicines12071586.

Soluble CD26: From Suggested Biomarker for Cancer Diagnosis to Plausible Marker for Dynamic Monitoring of Immunotherapy.

Kotrulev M, Gomez-Tourino I, Cordero O Cancers (Basel). 2024; 16(13).

PMID: 39001488 PMC: 11240764. DOI: 10.3390/cancers16132427.

Fibroblast activation protein: Pivoting cancer/chemotherapeutic insight towards heart failure.

Gehris J, Ervin C, Hawkins C, Womack S, Churillo A, Doyle J Biochem Pharmacol. 2023; 219:115914.

PMID: 37956895 PMC: 10824141. DOI: 10.1016/j.bcp.2023.115914.

Renal cancer secretome induces migration of mesenchymal stromal cells.

Poplawski P, Zarychta-Wisniewska W, Burdzinska A, Boguslawska J, Adamiok-Ostrowska A, Hanusek K Stem Cell Res Ther. 2023; 14(1):200.

PMID: 37563650 PMC: 10413545. DOI: 10.1186/s13287-023-03430-4.

Comparison of DPPIV Levels in Serum and Tumour of OSCC Patients and Its Correlation with Active Matrix Metalloproteinases 2 and 9.

Taheri A, Lashkarbolouki T, Karimi A, Sirati-Sabet M, Karima S, Goudarzi A Asian Pac J Cancer Prev. 2023; 24(4):1343-1349.

PMID: 37116157 PMC: 10352756. DOI: 10.31557/APJCP.2023.24.4.1343.

References

Lu Z, Qi L, Bo X, Liu G, Wang J, Li G . Expression of CD26 and CXCR4 in prostate carcinoma and its relationship with clinical parameters. J Res Med Sci. 2014; 18(8):647-52. PMC: 3872602. View

Shirakawa J, Fujii H, Ohnuma K, Sato K, Ito Y, Kaji M . Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes. 2011; 60(4):1246-57. PMC: 3064098. DOI: 10.2337/db10-1338. View

Morimoto C, Torimoto Y, Levinson G, Rudd C, Schrieber M, Dang N . 1F7, a novel cell surface molecule, involved in helper function of CD4 cells. J Immunol. 1989; 143(11):3430-9. View

Torimoto Y, Dang N, Vivier E, Tanaka T, Schlossman S, Morimoto C . Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. J Immunol. 1991; 147(8):2514-7. View

Li K, Wohlford-Lenane C, Channappanavar R, Park J, Earnest J, Bair T . Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proc Natl Acad Sci U S A. 2017; 114(15):E3119-E3128. PMC: 5393213. DOI: 10.1073/pnas.1619109114. View

Angevin E, Isambert N, Trillet-Lenoir V, You B, Alexandre J, Zalcman G . First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers. Br J Cancer. 2017; 116(9):1126-1134. PMC: 5418443. DOI: 10.1038/bjc.2017.62. View

Nazarian A, Lawlor K, Yi S, Philip J, Ghosh M, Yaneva M . Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer. Mol Cell Proteomics. 2014; 13(11):3082-96. PMC: 4223493. DOI: 10.1074/mcp.M114.038836. View

Pang R, Lun Law W, Chu A, Poon J, Lam C, Chow A . A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell. 2010; 6(6):603-15. DOI: 10.1016/j.stem.2010.04.001. View

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. PMC: 7159299. DOI: 10.1016/S0140-6736(20)30183-5. View

10.

Takeda M, Ohe Y, Horinouchi H, Hida T, Shimizu J, Seto T . Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma. Lung Cancer. 2019; 137:64-70. DOI: 10.1016/j.lungcan.2019.09.010. View

11.

Dang N, Torimoto Y, Sugita K, Daley J, Schow P, Prado C . Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation. J Immunol. 1990; 145(12):3963-71. View

12.

Aytac U, Sato K, Yamochi T, Ohnuma K, Mills G, Morimoto C . Effect of CD26/dipeptidyl peptidase IV on Jurkat sensitivity to G2/M arrest induced by topoisomerase II inhibitors. Br J Cancer. 2003; 88(3):455-62. PMC: 2747550. DOI: 10.1038/sj.bjc.6600791. View

13.

Thompson M, Ohnuma K, Abe M, Morimoto C, Dang N . CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders. Mini Rev Med Chem. 2007; 7(3):253-73. DOI: 10.2174/138955707780059853. View

14.

De Chiara L, Rodriguez-Pineiro A, Rodriguez-Berrocal F, Cordero O, Martinez-Ares D, Paez de la Cadena M . Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas. BMC Cancer. 2010; 10:333. PMC: 2912863. DOI: 10.1186/1471-2407-10-333. View

15.

Yamochi T, Yamochi T, Aytac U, Sato T, Sato K, Ohnuma K . Regulation of p38 phosphorylation and topoisomerase IIalpha expression in the B-cell lymphoma line Jiyoye by CD26/dipeptidyl peptidase IV is associated with enhanced in vitro and in vivo sensitivity to doxorubicin. Cancer Res. 2005; 65(5):1973-83. DOI: 10.1158/0008-5472.CAN-04-2611. View

16.

Dang N, Torimoto Y, Shimamura K, Tanaka T, Daley J, Schlossman S . 1F7 (CD26): a marker of thymic maturation involved in the differential regulation of the CD3 and CD2 pathways of human thymocyte activation. J Immunol. 1991; 147(9):2825-32. View

17.

Amori R, Lau J, Pittas A . Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007; 298(2):194-206. DOI: 10.1001/jama.298.2.194. View

18.

Dang N, Aytac U, Sato K, OBrien S, Melenhorst J, Morimoto C . T-large granular lymphocyte lymphoproliferative disorder: expression of CD26 as a marker of clinically aggressive disease and characterization of marrow inhibition. Br J Haematol. 2003; 121(6):857-65. DOI: 10.1046/j.1365-2141.2003.04365.x. View

19.

Cordero O, Ayude D, Nogueira M, Rodriguez-Berrocal F, de la Cadena M . Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer. Br J Cancer. 2000; 83(9):1139-46. PMC: 2363587. DOI: 10.1054/bjoc.2000.1410. View

20.

Takasawa W, Ohnuma K, Hatano R, Endo Y, Dang N, Morimoto C . Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines. Biochem Biophys Res Commun. 2010; 401(1):7-12. DOI: 10.1016/j.bbrc.2010.08.112. View